Cadre (CDRE) Competitors $31.99 +0.18 (+0.57%) As of 07/8/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDRE vs. BLCO, NARI, IRTC, TMDX, SLNO, INSP, NVST, PRCT, LIVN, and WRBYShould you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Bausch + Lomb (BLCO), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Inspire Medical Systems (INSP), Envista (NVST), PROCEPT BioRobotics (PRCT), LivaNova (LIVN), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry. Cadre vs. Its Competitors Bausch + Lomb Inari Medical iRhythm Technologies TransMedics Group Soleno Therapeutics Inspire Medical Systems Envista PROCEPT BioRobotics LivaNova Warby Parker Cadre (NYSE:CDRE) and Bausch + Lomb (NYSE:BLCO) are both medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment. Does the media refer more to CDRE or BLCO? In the previous week, Bausch + Lomb had 5 more articles in the media than Cadre. MarketBeat recorded 7 mentions for Bausch + Lomb and 2 mentions for Cadre. Cadre's average media sentiment score of 0.42 beat Bausch + Lomb's score of 0.37 indicating that Cadre is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadre 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, CDRE or BLCO? Cadre has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Do analysts prefer CDRE or BLCO? Cadre currently has a consensus target price of $37.50, indicating a potential upside of 17.22%. Bausch + Lomb has a consensus target price of $15.58, indicating a potential upside of 11.31%. Given Cadre's stronger consensus rating and higher probable upside, analysts clearly believe Cadre is more favorable than Bausch + Lomb.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadre 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Bausch + Lomb 1 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.23 Do institutionals and insiders have more ownership in CDRE or BLCO? 44.0% of Cadre shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 37.0% of Cadre shares are owned by insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings & valuation, CDRE or BLCO? Cadre has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadre$567.56M2.29$36.13M$0.9533.67Bausch + Lomb$4.79B1.03-$317M-$1.03-13.59 Is CDRE or BLCO more profitable? Cadre has a net margin of 6.87% compared to Bausch + Lomb's net margin of -7.50%. Cadre's return on equity of 12.52% beat Bausch + Lomb's return on equity.Company Net Margins Return on Equity Return on Assets Cadre6.87% 12.52% 6.04% Bausch + Lomb -7.50%2.62%1.28% SummaryCadre beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks. Get Cadre News Delivered to You Automatically Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDRE vs. The Competition Export to ExcelMetricCadrePROTECTION IndustryIndustrials SectorNYSE ExchangeMarket Cap$1.29B$2.03B$7.50B$20.52BDividend Yield1.19%1.87%4.54%3.76%P/E Ratio33.6739.2324.7727.79Price / Sales2.294.89114.2140.48Price / Cash22.4660.4827.3122.26Price / Book4.179.534.354.58Net Income$36.13M$110.42M$790.28M$982.91M7 Day Performance0.34%1.88%1.49%0.41%1 Month Performance-8.81%5.46%4.56%3.59%1 Year Performance-7.49%201.26%31.90%14.47% Cadre Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDRECadre3.5527 of 5 stars$31.99+0.6%$37.50+17.2%-7.7%$1.29B$567.56M33.672,284BLCOBausch + Lomb3.1036 of 5 stars$13.83-0.4%$15.54+12.4%-8.2%$4.91B$4.79B-13.4313,500Analyst ForecastNARIInari MedicalN/A$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies1.0367 of 5 stars$139.22-2.3%$138.60-0.4%+40.4%$4.55B$591.84M-44.342,000News CoverageTMDXTransMedics Group1.5222 of 5 stars$125.17-3.1%$127.33+1.7%-16.4%$4.37B$441.54M92.04210SLNOSoleno Therapeutics4.7235 of 5 stars$85.27-1.6%$107.10+25.6%+101.0%$4.37BN/A-18.4630INSPInspire Medical Systems4.8272 of 5 stars$127.11-1.1%$211.91+66.7%-1.7%$3.79B$802.80M58.581,246News CoveragePositive NewsNVSTEnvista3.8065 of 5 stars$19.66-3.6%$20.23+2.9%+22.8%$3.46B$2.51B-3.0112,300PRCTPROCEPT BioRobotics2.6605 of 5 stars$56.97-1.6%$90.00+58.0%-9.8%$3.20B$249.12M-33.51430News CoverageAnalyst ForecastLIVNLivaNova3.2024 of 5 stars$45.58-1.2%$59.29+30.1%-9.6%$2.52B$1.25B-11.142,900Positive NewsWRBYWarby Parker1.9504 of 5 stars$21.40-3.8%$22.88+6.9%+45.0%$2.32B$771.32M-178.333,780 Related Companies and Tools Related Companies BLCO Alternatives NARI Alternatives IRTC Alternatives TMDX Alternatives SLNO Alternatives INSP Alternatives NVST Alternatives PRCT Alternatives LIVN Alternatives WRBY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CDRE) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadre Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadre With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDRE Stock Alerts